4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists
Saved in:
| Main Authors: | Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.12592 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ICOS and ICOS ligand: expression patterns and outcomes in oncology patients
by: Mina Nikanjam, et al.
Published: (2025-04-01) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
An iterative strategy to design 4-1BB agonist nanobodies de novo with generative AI models
by: Ivan Poddiakov, et al.
Published: (2025-07-01) -
4-1BB Antibodies in Oncology Clinical Trials: A Review
by: Robin Schwartz, et al.
Published: (2025-03-01) -
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
by: Razelle Kurzrock, et al.
Published: (2020-05-01)